Menopause

Annals of Internal Medicine

Volumn 150, Issue 7, 2009, Pages 1-16

  Col, Nananda F ^a   Fairfield, Kathleen M ^a   Ewan Whyte, Carol ^a   Miller, Heather ^a   Laine, Christine ^a   Goldmann, David R ^a   Sox, Harold C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959420545     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397]
2. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53. [PMID: 14709575]
3. McKinlay SM. The normal menopause transition: an overview. Maturitas. 1996;23:137-45. [PMID: 8735352]
4. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4:267-72. [PMID: 11770182]
5. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52:345-56. [PMID: 11330770]
6. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152:463-73. [PMID: 10981461]
7. Williams RE, Kalilani L, DiBenedetti DB, et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58:348-58. [PMID: 17964093]
8. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a metaanalysis. J Gen Intern Med. 2008;23:1507-13. [PMID: 18521690]
9. Nelson HD, Haney E, Humphrey L, et al. Management of menopause-related symptoms. Evidence Report/Technology Assessment No. 120. AHRQ publication no. 05-E016-2. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
10. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med. 2005;118 Suppl 12B:14-24. [PMID: 16414323]
11. Oldenhave A, Jaszmann LJ, Haspels AA, et al. Impact of climacteric on wellbeing. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772-80. [PMID: 8456878]
12. Wilkin JK. Flushing reactions: consequences and mechanisms. Ann Intern Med. 1981;95:468-76. [PMID: 6169300]
13. Sowers M, Luborsky J, Perdue C. Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN. Clin Endocrinol (Oxf). 2003;58:340-7. [PMID: 12608940]
14. Gold EB, Block G, Crawford S, et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol. 2004;159:1189-99. [PMID: 15191936]
15. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006;96:1226-35. [PMID: 16735636]
16. Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009. [PMID: 19188852]
17. Daley A, MacArthur C, Mutrie N, et al. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007:CD006108.[PMID: 17943886]
18. Nelson DB, Sammel MD, Freeman EW, et al. Effect of physical activity on menopausal symptoms among urban women. Med Sci Sports Exerc. 2008;40:50-8.[PMID: 18091021]
19. Daley A, Macarthur C, Stokes-Lampard H, et al. Exercise participation, body mass index, and health-related quality of life in women of menopausal age. Br J Gen Pract. 2007;57:130-5.[PMID: 17266830]
20. Schwingl PJ, Hulka BS, Harlow SD. Risk factors for menopausal hot flashes. Obstet Gynecol. 1994;84:29-34.[PMID: 8008318]
21. Avis NE, Stellato R, Crawford S, et al. Is there an association between menopause status and sexual functioning? Menopause. 2000;7:297-309.[PMID: 10993029]
22. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet. 2005;88:222-8.[PMID: 15779109]
23. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15:661-6.[PMID: 18698279]
24. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61:178-80.[PMID: 8293835]
25. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259-63.[PMID: 8794418]
26. Dennerstein L, Alexander JL, Kotz K. The menopause and sexual functioning: a review of the population- based studies. Annu Rev Sex Res. 2003;14:64-82.[PMID: 15287158]
27. Dennerstein L, Lehert P, Burger H, et al. Sexuality. Am J Med. 2005;118 Suppl 12B:59-63.[PMID: 16414328]
28. Avis NE, Zhao X, Johannes CB, et al. Correlates of sexual function among multi-ethnic middleaged women: results from the Study of Women's Health Across the Nation (SWAN). Menopause. 2005;12:385-98.[PMID: 16037753]
29. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935-48.[PMID: 15728164]
30. Hay-Smith EJ, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2006:CD005654.[PMID: 16437536]
31. Adams E, Thomson A, Maher C, et al. Mechanical devices for pelvic organ prolapse in women. Cochrane Database Syst Rev. 2004:CD004010.[PMID: 15106231]
32. Maher C, Baessler K, Glazener CM, et al. Surgical management of pelvic organ prolapse in women: a short version Cochrane review. Neurourol Urodyn. 2008;27:3-12.[PMID: 18092333]
33. Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med. 2008;148:459-73.[PMID: 18268288]
34. Rowland N, Bower P, Mellor C, et al. Effectiveness and cost effectiveness of counselling in primary care. Cochrane Database Syst Rev. 2001:CD001025.[PMID: 11686973]
35. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12.[PMID: 15082697]
36. Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. 2004:CD000402.[PMID: 15266429]
37. Col NF, Weber G, Stiggelbout A, et al. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med. 2004;164:1634-40.[PMID: 15302633]
38. WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036-45.[PMID: 18319414]
39. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-62.[PMID: 12771112]
40. Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004:CD002978.[PMID: 15495039]
41. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-20.[PMID: 15069049]
42. Wren BG, Champion SM, Willetts K, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003;10:13-8.[PMID: 12544672]
43. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065-79.[PMID: 11384629]
44. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med. 2005;118 Suppl 12B:163-5.[PMID: 16414343]
45. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142:855-60.[PMID: 15897536]
46. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA. 2006;295:2057-71.[PMID: 16670414]
47. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145:869-79.[PMID: 17179056]
48. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause. 2003;10:465-76.[PMID: 14501609]
49. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003;290:207-14.[PMID: 12851275]
50. Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med. 2005;118 Suppl 12B:98-108.[PMID: 16414334]
51. Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). 2005;14:634-49.[PMID: 16181020]
52. Carpenter JS, Neal JG. Other complementary and alternative medicine modalities: acupuncture, magnets, reflexology, and homeopathy. Am J Med. 2005;118 Suppl 12B:109-17.[PMID: 16414335]
53. Kronenberg F, Fugh- Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-13.[PMID: 12435217]
54. Borud EK, Alraek T, White A, et al. The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial. BMC Complement Altern Med. 2007;7:6.[PMID: 17324253]
55. Ahlborg HG, Johnell O, Turner CH, et al. Bone loss and bone size after menopause. N Engl J Med. 2003;349:327-34.[PMID: 12878739]
56. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595-603.[PMID: 16093468]
57. Khosla S, Melton LJ 3rd. Clinical practice. Osteopenia. N Engl J Med. 2007;356:2293-300.[PMID: 17538088]
58. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-8.[PMID: 12230355]
59. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168:370-7; quiz 345. [PMID: 18299491]
60. Linkov F, Edwards R, Balk J, et al. Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors. Eur J Cancer. 2008;44:1632-44.[PMID: 18514507]
61. ACOG Taske Force for Hormone Therapy American College of Obstetricians and Gynecologists Women's Health Care Physicians. Summary of balancing risks and benefits. Obstet Gynecol. 2004;104:128S-129S.[PMID: 15458943]
62. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15:584-602.[PMID: 18580541]
63. National Institutes of Health. National Institutes of Health Stateof- the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142:1003-13.[PMID: 15968015]